- Agenus Inc. (AGEN, Financial) to present new data at ASCO 2025 on botensilimab and balstilimab for colorectal and pancreatic cancers.
- Presentations include a study on T-cell dynamics in colorectal cancer and trial designs for pancreatic cancer therapies.
- Clinical trials explore botensilimab-enhanced therapies in both refractory and untreated cancer cases.
Agenus Inc. (AGEN), a key player in immuno-oncology, has announced the presentation of three studies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting scheduled from May 30 to June 3 in Chicago, Illinois.
The highlight includes a poster presentation detailing novel translational data on T-cell dynamics induced by botensilimab and balstilimab in mismatch repair-proficient (pMMR) and microsatellite stable (MSS) metastatic colorectal cancer (mCRC). This study will be shared on May 31, 2025, from 9:00 AM to 12:00 PM CDT as part of the Gastrointestinal Cancer—Colorectal and Anal session.
In addition, Agenus will unveil two trials-in-progress presentations that focus on ongoing studies using botensilimab-based combinations in advanced pancreatic cancer. These will also be presented on May 31, 2025, during the Gastrointestinal Cancer sessions and include a phase 2 study combining botensilimab with AGEN1423 and other agents, as well as an open-label phase 1 trial with innovative combination therapies.
The botensilimab/balstilimab program, which has treated approximately 1,100 patients in clinical trials, aims to enhance therapeutic responses across multiple advanced cancers, including those unresponsive to standard treatments, by boosting both innate and adaptive immune responses.
Agenus Inc., established in 1994 and headquartered in Lexington, MA, continues to expand its comprehensive pipeline of immunotherapeutic agents, enhancing cancer treatment options and targeting unmet needs in oncology.
